WallStSmart

Inogen Inc (INGN)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 10496% more annual revenue ($37.54B vs $354.30M). MDT leads profitability with a 13.9% profit margin vs -6.9%. MDT appears more attractively valued with a PEG of 1.65. MDT earns a higher WallStSmart Score of 68/100 (B-).

INGN

Hold

49

out of 100

Grade: D+

Growth: 5.3Profit: 2.0Value: 5.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.71

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INGNUndervalued (+88.9%)

Margin of Safety

+88.9%

Fair Value

$55.09

Current Price

$5.31

$49.78 discount

UndervaluedFair: $55.09Overvalued
MDTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$94.43

Current Price

$90.96

$3.47 discount

UndervaluedFair: $94.43Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INGN3 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

EPS GrowthGrowth
87.3%10/10

Earnings expanding 87.3% YoY

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$116.35B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

Areas to Watch

INGN4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
3.0%4/10

3.0% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Market CapQuality
$143.04M3/10

Smaller company, higher risk/reward

PEG RatioValuation
3.482/10

Expensive relative to growth rate

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : INGN

The strongest argument for INGN centers on Price/Book, EPS Growth, Debt/Equity.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bear Case : INGN

The primary concerns for INGN are Revenue Growth, Altman Z-Score, Market Cap.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

INGN profiles as a turnaround stock while MDT is a value play — different risk/reward profiles.

INGN carries more volatility with a beta of 1.60 — expect wider price swings.

MDT is growing revenue faster at 13.7% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (68/100 vs 49/100) and 13.7% revenue growth. INGN offers better value entry with a 88.9% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Inogen Inc

HEALTHCARE · MEDICAL DEVICES · USA

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?